Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 3/20 | 0.57 |
| ▸ | BRAF | P15056 | 3/20 | 0.57 |
| ▸ | KRAS | P01116 | 2/20 | 0.57 |
| ▸ | KDR | P35968 | 2/20 | 0.57 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.57 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.57 |
| ▸ | ARAF | P10398 | 1/20 | 0.55 |
| ▸ | ABL1 | P00519 | 17/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15289663 | 0.89 | RAF1 (0.52) | RAF1BRAFKRASKDRMAP2K2 | |
| SCHEMBL15289508 | 0.87 | ABL1 (0.54) | RAF1BRAFKRASKDRMAP2K2 | |
| SCHEMBL16632256 | 0.86 | BRAF (0.72) | RAF1BRAFKRASKDRMAP2K2 | |
| SCHEMBL15272566 | 0.86 | BRAF (0.67) | RAF1BRAFKRASKDRMAP2K2 | |
| SCHEMBL15270619 | 0.86 | BRAF (0.53) | RAF1BRAFKRASKDRMAP2K2 | |
| SCHEMBL16632301 | 0.85 | ABL1 (0.57) | RAF1BRAFKRASKDRABL1 | |
| SCHEMBL16641788 | 0.85 | BRAF (0.63) | RAF1BRAFKRASKDRMAP2K2 | |
| SCHEMBL15270481 | 0.85 | BRAF (0.71) | RAF1BRAFKRASKDRMAP2K2 | |
| Hydrochloric Acid SCHEMBL16632297 | 0.84 | BRAF (0.70) | RAF1BRAFKRASKDRMAP2K2 | |
| SCHEMBL15273127 | 0.84 | BRAF (0.80) | RAF1BRAFKRASKDRMAP2K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9187474-B2 | Raf inhibitor compounds | DECIPHERA PHARMACEUTICALS, LLC (US) | 2015-11-17 | — | — | US | disclosed |
| US-20150105367-A1 | RAF INHIBITOR COMPOUNDS | DECIPHERA PHARMACEUTICALS, LLC | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150105367-A1 | RAF INHIBITOR COMPOUNDS | BRAF, RAF1, NRAS | RAF1 2/4885BRAF 1/4885KRAS 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.